BR112022000113A2 - Processos para preparação de inibidores de calicreí-na de plasma - Google Patents

Processos para preparação de inibidores de calicreí-na de plasma

Info

Publication number
BR112022000113A2
BR112022000113A2 BR112022000113A BR112022000113A BR112022000113A2 BR 112022000113 A2 BR112022000113 A2 BR 112022000113A2 BR 112022000113 A BR112022000113 A BR 112022000113A BR 112022000113 A BR112022000113 A BR 112022000113A BR 112022000113 A2 BR112022000113 A2 BR 112022000113A2
Authority
BR
Brazil
Prior art keywords
group
plasma kallikrein
processes
kallikrein inhibitors
preparing plasma
Prior art date
Application number
BR112022000113A
Other languages
English (en)
Inventor
Baburaj Krishnan
Ganapati Bhat
Sukanto Sinha
Tamie Chilcote
Vineet Malik
Original Assignee
Activesite Pharmaceuticals Inc
Rezolute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activesite Pharmaceuticals Inc, Rezolute Inc filed Critical Activesite Pharmaceuticals Inc
Publication of BR112022000113A2 publication Critical patent/BR112022000113A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

processo para preparação de inibidores de calicreína de plasma. a presente invenção refere-se a um processo para preparar e purificar um composto de fórmula i é fornecido: (fórmula i), ou um sal do mesmo, em que o subscrito m é um número inteiro de 0 a 3; cada ra é independentemente selecionado do grupo que con-siste em (c3-c8)cicloalquila, (c1-c4)haloalquila, halogênio, -oh, -or1, -sh, -sr1, -s(o)r1, -s(o)2r1, -so2nh2, -c(o)nh2, -c(o)nhr1, -c(o)n (r1)2, -c(o)r1, -c(o)h, -co2h, -co2r1, -no2, -nh2, -nhr1, -n(r1)2, em que cada r1 é independentemente (c1-c8)alquila; l é um grupo de ligação selecionado do grupo que consiste em uma ligação ou ch2; qa, qb, e qc são, cada qual, membros independentemente se-lecionados do grupo que consiste em n, s, o e c(rq) em que cada rq é independentemente selecionado do grupo que consiste em h, c1-8 alqui-la, halo e fenila e o anel tendo qa, qb, qc e y como vértices de anel é um anel de cinco membros tendo duas ligações duplas; e y é selecionado do grupo que consiste em c e n.
BR112022000113A 2019-07-08 2020-07-07 Processos para preparação de inibidores de calicreí-na de plasma BR112022000113A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962871526P 2019-07-08 2019-07-08
PCT/US2020/040958 WO2021007190A1 (en) 2019-07-08 2020-07-07 Processes for preparing plasma kallikrein inhibitors

Publications (1)

Publication Number Publication Date
BR112022000113A2 true BR112022000113A2 (pt) 2022-03-15

Family

ID=74102932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000113A BR112022000113A2 (pt) 2019-07-08 2020-07-07 Processos para preparação de inibidores de calicreí-na de plasma

Country Status (10)

Country Link
US (2) US11267790B2 (pt)
EP (1) EP3997060A4 (pt)
JP (1) JP2022541398A (pt)
KR (1) KR20220058530A (pt)
AU (1) AU2020311879A1 (pt)
BR (1) BR112022000113A2 (pt)
CA (1) CA3145299A1 (pt)
IL (1) IL289287A (pt)
MX (1) MX2022000320A (pt)
WO (1) WO2021007190A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220058530A (ko) 2019-07-08 2022-05-09 레졸루트 인크 혈장 칼리크레인 억제제의 제조 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
EP0470246B1 (en) 1990-02-28 1995-06-28 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1808440B1 (en) * 2000-08-11 2011-07-27 Wilex AG Non-covalent inhibitors of urokinase and blood vessel formation
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
MX2007002391A (es) * 2004-09-06 2007-04-23 Hoffmann La Roche Derivados de 4-aminometil benzamida y su uso como inhibidores del factor viia.
CA2591786C (en) 2004-12-23 2013-07-16 Bernhard Nieswandt Prevention of thrombus formation and/or stabilization
AU2007281220B2 (en) 2006-07-31 2013-08-15 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2009097141A1 (en) 2008-01-31 2009-08-06 Joslin Diabetes Center Methods for treatment of kallikrein-related disorders
CN102464701B (zh) 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
WO2012142308A1 (en) * 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
GB201213700D0 (en) * 2012-08-01 2012-09-12 Proximagen Ltd Receptor antagnists II
KR20220058530A (ko) 2019-07-08 2022-05-09 레졸루트 인크 혈장 칼리크레인 억제제의 제조 방법

Also Published As

Publication number Publication date
US20230234927A1 (en) 2023-07-27
CA3145299A1 (en) 2021-01-14
JP2022541398A (ja) 2022-09-26
AU2020311879A1 (en) 2022-01-27
IL289287A (en) 2022-02-01
EP3997060A1 (en) 2022-05-18
EP3997060A4 (en) 2023-07-19
CN114502531A (zh) 2022-05-13
US20210009526A1 (en) 2021-01-14
WO2021007190A1 (en) 2021-01-14
MX2022000320A (es) 2022-04-20
US11267790B2 (en) 2022-03-08
KR20220058530A (ko) 2022-05-09

Similar Documents

Publication Publication Date Title
CO6321272A2 (es) Fosfatos ciclicos de nucleosidos.
CR20190124A (es) Inhibidores de ssao de aminopirimidina
CY1118102T1 (el) Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων
BR112015025716A2 (pt) pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv
AR105459A1 (es) Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr
BR112017005767A2 (pt) composições de limpeza contendo uma polieteramina
BRPI0519316B8 (pt) composição aquosa herbicida, e, processo para a preparação de uma composição
BR112022002953A2 (pt) Composições e métodos para condicionamento não tóxico
BR112022000113A2 (pt) Processos para preparação de inibidores de calicreí-na de plasma
BRPI0407284A (pt) Bactérias e processo para produção de compostos quìmicos pelas bactérias i
BRPI0612926B8 (pt) compostos fluorados de 4-(2-amino-1-hidroxietila)fenol como agonistas de receptores b2 adrenérgicos, composição farmacêutica, combinação e uso de um composto
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
BR112014011670A2 (pt) anticorpo anti- adrenomedulina (adm) ou fragmento de anticorpo anti -adm ou uma estrutura anti- adm não-ig para utilização em terapia
GT200800154A (es) N-sulfonilacion selectiva de alcoholes 2-amino trifluoroalquilo sustituidos
JP2010077130A5 (pt)
BR112019002417A2 (pt) cristalização de glicosídeos de esteviol
BR0113940A (pt) Método para a purificação de ácidos alfa-hidróxi em uma escala industrial
ECSP23019419A (es) Proceso e intermedios para preparar un inhibidor de jak1
CO2021017343A2 (es) Formas de sales cristalinas de un inhibidor de cinasas
BR112014001299A2 (pt) forma cristalina do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzenossulfonamida
CL2020003444A1 (es) Cuerpo conformado basado en óxido de magnesio y carbonato de calcio y método para su preparación
BR112018075803A2 (pt) processo melhorado para a preparação de carbamatos
AR054048A1 (es) Compuesto de 2- amino-4-oxo-1,3-tiazol-5- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del mismo para preparar un medicamento
AR053176A1 (es) Anilidas de acido nicotinico, procedimiento para su preparacion y productos que los contienen para combatir hongos nocivos